Survivin

Reference work entry

Abstract

Survivin is abundantly and ubiquitously present in development, undetectable in most adult tissues, and prominently reexpressed in virtually every human cancer. Thus, one of the most significant features of survivin is its preferential expression in tumor vs. normal tissues. Even though a few normal cells do express survivin, e.g., thymocytes, CD34+ bone marrow-derived stem cells, and basal colonic epithelial cells (Altieri, Nat Rev Cancer 3:46–54, 2003), under physiological conditions, survivin is undetectable in most terminally differentiated normal tissues (Altieri et al., Lab Invest 79:1327–1333, 1999). In contrast, survivin is overexpressed in almost all cancers including lung, colon, breast, pancreas, stomach, liver, ovaries, and prostate cancer, as well as melanoma and hematopoietic malignancies (Ambrosini et al., J Biol Chem 273:11177–11182, 1998; Adida et al., Blood 96:1921–1925, 2000; Grossman et al., J Invest Dermatol 113:1076–1081, 1999). Data from a large analysis of human transcripts revealed survivin as the fourth most highly expressed protein in human cancer tissue compared to normal tissue (Velculescu et al., Nat Genet 23:387–388, 1999).

Keywords

Survivin Anti-survivin T cells Apoptosis inhibition Apoptosis proteins Chemotherapeutic agents Immunogenicity Immunohistochemistry In cancers In tumor vs. normal tissues Inhibitory T-cell ligand B7-H1 Regulation of mitosis Standard immunohistochemistry Synthetic peptides Therapeutic vaccinations Vaccination Vs. T-cell responses 

References

  1. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–5.PubMedGoogle Scholar
  2. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46–54.CrossRefPubMedGoogle Scholar
  3. Altieri DC, Marchisio PC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest. 1999;79:1327–33.PubMedGoogle Scholar
  4. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–82.CrossRefPubMedGoogle Scholar
  5. Andersen MH, Pedersen LO, Becker JC, thor Straten P. Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res. 2001a;61:869–72.PubMedGoogle Scholar
  6. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001b;61:5964–8.PubMedGoogle Scholar
  7. Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F, Mezzanzanica D, Costa A, Andreola S, Leo E, Parmiani G, Castelli C. The apoptosis inhibitor protein survivin induces tumor-specific CD8(+) and CD4(+) T cells in colorectal cancer patients. Cancer Res. 2003;63:4507–15.PubMedGoogle Scholar
  8. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A. 2004;101:13239–44.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. 2004;103:2046–54.CrossRefPubMedGoogle Scholar
  10. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8:808–15.PubMedGoogle Scholar
  11. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–7.PubMedGoogle Scholar
  12. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–81.CrossRefPubMedGoogle Scholar
  13. Hadrup SR, Gehl J, Sorensen RB, Geertsen PF, Straten PT, Andersen MH. Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther. 2006;5:480–2.CrossRefPubMedGoogle Scholar
  14. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–23.CrossRefPubMedGoogle Scholar
  15. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–4.PubMedGoogle Scholar
  16. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1749–56.CrossRefPubMedGoogle Scholar
  17. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–59.CrossRefPubMedGoogle Scholar
  18. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–4.CrossRefPubMedGoogle Scholar
  19. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275–92.CrossRefPubMedGoogle Scholar
  20. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60:2805–9.PubMedGoogle Scholar
  21. Otto K, Andersen MH, Eggert AO, Keikavoussi P, Pedersen LO, Rath JC, Bock M, Brocker EB, thor Straten P, Kampgen E, Becker JC. Therapy-induced T cell responses against the universal tumor antigen survivin. Vaccine. 2004;23:884–9.CrossRefGoogle Scholar
  22. Pennati M, Binda M, Colella G, Zoppe’ M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene. 2004;23:386–94.CrossRefPubMedGoogle Scholar
  23. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9:6523–33.PubMedGoogle Scholar
  24. Reker S, Becker JC, Svane IM, Ralfkiaer E, thor Straten P, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004a;108:937–41.CrossRefPubMedGoogle Scholar
  25. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004b;3:173–9.CrossRefPubMedGoogle Scholar
  26. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3:401–10.CrossRefPubMedGoogle Scholar
  27. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102:571–6.CrossRefPubMedGoogle Scholar
  28. Siegel S, Steinmann J, Schmitz N, Stuhlmann R, Dreger P, Zeis M. Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia. 2004;18:2046–7.CrossRefPubMedGoogle Scholar
  29. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285:324–8.CrossRefPubMedGoogle Scholar
  30. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452–3.CrossRefPubMedGoogle Scholar
  31. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, Hamada H. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 2004;10:162–71.CrossRefPubMedGoogle Scholar
  32. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW. Analysis of human transcriptomes. Nat Genet. 1999;23:387–8.CrossRefPubMedGoogle Scholar
  33. Wacheck V, Selzer E, Gunsberg P, Lucas T, Meyer H, Thallinger C, Monia BP, Jansen B. Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells. Br J Cancer. 2003;89:1352–7.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol. 2003;30:133–42.CrossRefPubMedGoogle Scholar
  35. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother. 2006;55:1294–8.CrossRefPubMedGoogle Scholar
  36. Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005;65:553–61.PubMedGoogle Scholar
  37. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A. 2004;101:15100–5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of HematologyCenter for Cancer Immune Therapy (CCIT), University Hospital HerlevHerlevDenmark
  2. 2.Translational Skin Cancer Research – tscr / L441, DermatologieUniversitätsklinikum EssenEssenGermany

Personalised recommendations